Breast Cancer

>

Latest News

PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer
Addition of Inavolisib Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer

May 23rd 2025

The phase 3 INAVO120 trial showed that overall survival significantly improved with the addition of inavolisib to palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer.

Amanda Brink discusses AI-driven image analysis in HER2 scoring in breast cancer.
Opinion: Artificial Intelligence Enhances Precision in HER2 Scoring for Breast Cancer

May 19th 2025

Anatomical image of a person with a breast tumor
Ribociclib Combo Produces Similar pCR to Chemo in HR+ Breast Cancer

May 18th 2025

Graphic of a breast with a tumor
T-DXd Regimen Improves pCR in Early HER2+ Breast Cancer

May 13th 2025

Line illustration of a clipboard that says "FDA" with an approval mark in front on a cornflower blue background
A Snapshot of April FDA Approvals in Oncology for Nurses and APPs

May 1st 2025

Video Series
Video Interviews
Podcasts
The Vitals
Oncology Nursing News
Are Hearing Tests Necessary For Adult Cancer Survivors?
Sarah Donahue Highlights Destiny-04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast Cancer
Key Advances in Cancer Survivorship Toxicity Management
Loyda Braithwaite Discusses Evolving Treatment Options in HR+ Breast Cancer
Latest CME Events & Activities

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

View More

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

View More

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

View More

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

View More

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

View More

Annual Hawaii Cancer Conference

January 24-25, 2026

Register Now!

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register Now!

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

More News